

M.-J. SALLES<sup>1,2</sup>, D. HERVE<sup>2</sup>, M.J. MILLAN<sup>1</sup>, J.-A. GIRAULT<sup>2</sup>, C. MANNOURY LA COUR<sup>1</sup>  
<sup>1</sup>IdR Servier, Croissy-sur-Seine, France, <sup>2</sup>Institut du Fer à Moulin, Inserm, UMR-S 839, Paris, France

No conflict of interest

**INTRODUCTION**

> Increasing evidences suggest a role for the serine/threonine kinase Akt and its downstream substrate glycogen synthase kinase-3β (GSK-3β) in the etiology of schizophrenia, a psychiatric disorder characterized by a deregulation of the dopaminergic system.


> mTOR (mammalian Target Of Rapamycin), a serine/threonine kinase activated by Akt, acts as a regulator of the CNS neuroplasticity playing a role in cognition and neuroprotection. Inhibition of the mTOR pathway was shown to improve cognitive functions which are impaired in schizophrenic patients (Ehninger et al., 2008).

> The papers about the effects of stimulation of D<sub>2</sub>-type receptors on the regulation of Akt and GSK-3β are apparently contradictory. This stimulation was reported to increase Akt and GSK-3β phosphorylation in various cell lines expressing D<sub>2</sub>-type receptors, such as striatal neurons (Brami-Cherrier et al., 2002), PC12, EM4 and CHO cells (Zapata et al., 2007; Nair and Olanow, 2008; Chen et al., 2009; Mannoury la Cour et al., 2011). In contrast, it was found to decrease Akt and GSK-3β phosphorylation in the striatum *in vivo* (Beaulieu et al., 2007).


> However, the activation of Akt/GSK-3β signaling in the cell models displayed a quick onset (few mins) whereas the *in vivo* inhibition slowly developed with a maximum 90 min after the beginning of stimulation. In the present study, we investigated the possibility of a transient activation of Akt/GSK-3β *in vivo* shortly after stimulation of dopamine D<sub>2</sub> and D<sub>3</sub> receptors. Our aims were :

- to examine the kinetic of short-term effects on Akt and its effectors, GSK-3β and mTOR pathways after acute treatment with quinolorane, a D<sub>2</sub>/D<sub>3</sub> receptor agonist, in the rat striatum and nucleus accumbens.
- to determine the role of dopamine D<sub>3</sub> receptor subtype in the short-term effects of quinolorane.


**Quinolorane induced a transient activation of Akt/GSK-3β and mTOR signaling in the rat striatum and nucleus accumbens**




**Raclopride prevented quinolorane-induced phosphorylations of Akt, GSK-3β and downstream targets of mTOR**




**Quinolorane-induced phosphorylations occurred in both D1R+ and D1R- neurons**



**Selective D<sub>3</sub> receptor antagonist S33084 blocked quinolorane-elicited effects upon Akt/GSK-3β and mTOR signaling**



**Quinolorane failed to increase phosphorylation of Akt, GSK-3β and mTOR targets in D<sub>3</sub>-KO mice**



**CONCLUSIONS / PERSPECTIVES**

**Conclusions**

> Quinolorane induced a transient increase of phosphorylation of Akt, GSK-3β and mTOR downstream effectors in the rat striatum and nucleus accumbens with a maximal effect 10 min after injection. All protein phosphorylation levels returned to baseline at 20 min.

> Pharmacological and genetic approaches revealed a major role for D<sub>3</sub> receptors in the effects of quinolorane, though a contribution of D<sub>2</sub> receptors cannot be excluded.

**Perspectives**

> Testing the influence of the mTORC1 inhibitor, rapamycin, on quinolorane-induced activation of the mTOR pathway.

> Evaluating the action of quinolorane in the cortex, a structure involved in the pro-cognitive effects of D<sub>3</sub> receptor antagonists and rapamycin.

> Characterizing the molecular mechanisms involved in the recruitment of Akt by D<sub>2</sub> and D<sub>3</sub> receptor activation (e.g; role of Src, PI3-Kinase).